These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32114955)

  • 21. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 22. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.
    Guled M; Lahti L; Lindholm PM; Salmenkivi K; Bagwan I; Nicholson AG; Knuutila S
    Genes Chromosomes Cancer; 2009 Jul; 48(7):615-23. PubMed ID: 19396864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-7 is expressed in malignant mesothelioma and has a prognostic value.
    Mai HL; Deshayes S; Nguyen TV; Dehame V; Chéné AL; Brouard S; Blanquart C
    Mol Oncol; 2022 Oct; 16(20):3606-3619. PubMed ID: 36054746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
    Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
    J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
    Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
    Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
    De Santi C; Melaiu O; Bonotti A; Cascione L; Di Leva G; Foddis R; Cristaudo A; Lucchi M; Mora M; Truini A; Tironi A; Murer B; Boldorini R; Cipollini M; Gemignani F; Gasparini P; Mutti L; Landi S
    Sci Rep; 2017 Jun; 7(1):3140. PubMed ID: 28600498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.
    Benjamin H; Lebanony D; Rosenwald S; Cohen L; Gibori H; Barabash N; Ashkenazi K; Goren E; Meiri E; Morgenstern S; Perelman M; Barshack I; Goren Y; Edmonston TB; Chajut A; Aharonov R; Bentwich Z; Rosenfeld N; Cohen D
    J Mol Diagn; 2010 Nov; 12(6):771-9. PubMed ID: 20864637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure.
    Metintas M; Metintas S; Ak G; Erginel S; Alatas F; Kurt E; Ucgun I; Yildirim H
    Respirology; 2008 Jan; 13(1):117-21. PubMed ID: 18197921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
    Busacca S; Germano S; De Cecco L; Rinaldi M; Comoglio F; Favero F; Murer B; Mutti L; Pierotti M; Gaudino G
    Am J Respir Cell Mol Biol; 2010 Mar; 42(3):312-9. PubMed ID: 19502386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
    Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
    Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres.
    Proietti L; Spicuzza L; Di Maria A; Polosa R; Sebastian Torres E; Asero V; Di Maria GU
    Monaldi Arch Chest Dis; 2006 Dec; 65(4):210-6. PubMed ID: 17393666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
    Kokturk N; Firat P; Akay H; Kadilar C; Ozturk C; Zorlu F; Gungen Y; Emri S
    Lung Cancer; 2005 Nov; 50(2):189-98. PubMed ID: 16043260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
    Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
    EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of MicroRNAs as early biomarkers of asbestos-related lung cancer: A systematic review and meta-analysis.
    Mukhopadhyay D; Cocco P; Orrù S; Cherchi R; De Matteis S
    Pulmonology; 2024 Feb; ():. PubMed ID: 38402124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.
    Xu J; Alexander DB; Iigo M; Hamano H; Takahashi S; Yokoyama T; Kato M; Usami I; Tokuyama T; Tsutsumi M; Tamura M; Oguri T; Niimi A; Hayashi Y; Yokoyama Y; Tonegawa K; Fukamachi K; Futakuchi M; Sakai Y; Suzui M; Kamijima M; Hisanaga N; Omori T; Nakae D; Hirose A; Kanno J; Tsuda H
    Cancer Sci; 2015 Jul; 106(7):825-32. PubMed ID: 25940505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma.
    Okado S; Kato T; Hanamatsu Y; Emoto R; Imamura Y; Watanabe H; Kawasumi Y; Kadomatsu Y; Ueno H; Nakamura S; Mizuno T; Takeuchi T; Matsui S; Chen-Yoshikawa TF
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
    Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.
    Ivanova AV; Ivanov SV; Prudkin L; Nonaka D; Liu Z; Tsao A; Wistuba I; Roth J; Pass HI
    Mol Cancer; 2009 Oct; 8():91. PubMed ID: 19852844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.